Solve GNE

About Solve GNE

Solve GNE is a community dedicated to finding a cure for GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), an ultra-rare genetic disorder causing progressive muscle weakness. Their mission is to advance research and develop therapies to help patients affected by this condition.

Products & Services

Gene Therapy for HIBM:Collaborating with organizations like Gradalis and Genosera to develop novel gene therapies, including bicistronic AAV therapies, targeting GNE Myopathy.

Research and Clinical Trials:Working with leading researchers and institutions to advance cutting-edge discoveries from lab to clinic, including CRISPR-based gene editing for GNE Myopathy.

Specialties

Gene Therapy CRISPR Gene Editing GNE Myopathy Research Rare Genetic Disorders

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Non-profit fundraising T: - FT: Non-profit fundraising	A: 2500000 MR: - FA: over $2.5 million FAN: 2500000	D: 2023-07-31 FD: 2023-07-31	-

Non-profit fundraising Latest

2023-07-31

$2.5M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Gregory Newby

Assistant Professor of Genetic Medicine

J

John Day

Professor of Neurology

N

Natalia Gomez-Ospina

Assistant Professor of Pediatrics (Genetics)

F

Fraser Wright

Professor of Pediatrics

P

Paul Martin

Doctor

P

Paul T. Martin

Principal Investigator and Professor

View 7 more team members with Pro

Unlock Full Team Directory

Recent News

Solve GNE Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised